Explore

Healthy Living

News

Health A-Z

Calculators

Articles

Drugs

Directories

Education

More

Search Medindia

Medindia » SGLT2 Inhibitors: An Evolution in Diabetes Mellitu

SGLT2 Inhibitors: An Evolution in Diabetes Mellitu News, Research and Latest Updates

Keep abreast with the latest news related to SGLT2 Inhibitors: An Evolution in Diabetes Mellitu there are 62 news items on SGLT2 Inhibitors: An Evolution in Diabetes Mellitu that covers updates, breakthroughs and in-depth reports.

We provide you with a free downloadable secure widget for your website to carry news related to SGLT2 Inhibitors: An Evolution in Diabetes Mellitu.

Empagliflozin and Intranasal Insulin May Slow Alzheimer's Decline

Empagliflozin and Intranasal Insulin May Slow Alzheimer's Decline

Two existing medications show promise in improving brain health and cognitive function in early Alzheimer’s disease.

Novel Type 1 Diabetes Treatment Combines Glucagon and Insulin in One Shot

Novel Type 1 Diabetes Treatment Combines Glucagon and Insulin in One Shot

Can one molecule replace separate insulin and glucagon shots in Type 1 diabetes? New research shows it might be possible.

Mitochondria: A Potential Target for Diabetes Treatment

Mitochondria: A Potential Target for Diabetes Treatment

Mitochondrial dysfunction affects insulin-producing β-cells, linking it to diabetes. Targeting mitochondria could open new paths for diabetes treatment.

Fat-Derived Cellular Therapy: A New Hope for Diabetes Treatment

Fat-Derived Cellular Therapy: A New Hope for Diabetes Treatment

Fat-Derived cellular therapy offers a promising new approach for diabetes, using cells from body fat to improve insulin function and potentially reverse the disease.

Impact of Intensive Diabetes Treatment on Periodontal Health

Impact of Intensive Diabetes Treatment on Periodontal Health

A study reveals that intensive diabetes treatment improves both blood sugar control and periodontal inflammation, showing a link between diabetes management and gum health.

Heart Attack Patients Benefit from SGLT2 Inhibitor Empagliflozin

Heart Attack Patients Benefit from SGLT2 Inhibitor Empagliflozin

Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to improve outcomes.

Semaglutide's Multifaceted Benefits in Diabetes Treatment

Semaglutide's Multifaceted Benefits in Diabetes Treatment

Semaglutide drastically decreases the likelihood of adverse events among patients with type 2 diabetes.

Diabetes Drug Dapagliflozin Proves Effective in Kidney Disease Patients

Diabetes Drug Dapagliflozin Proves Effective in Kidney Disease Patients

Dapagliflozin, the drug used to treat diabetes was found to be a cost-effective treatment in patients with chronic kidney disease in addition to standard care.

Dapagliflozin May Benefit Hospitalized COVID-19 Patients

Dapagliflozin May Benefit Hospitalized COVID-19 Patients

Dapagliflozin was well-tolerated irrespective of kidney function in COVID-19 patients who were hospitalized, as per the recent randomized clinical trial.

SGLT2 Inhibitors Provide Kidney, Heart Protection

SGLT2 Inhibitors Provide Kidney, Heart Protection

Sodium-glucose cotransporter 2(SGLT2) inhibitors intake was linked to a lower risk of developing cardiovascular disease and kidney failure among patients with type 1 diabetes.

Download SGLT2 Inhibitors: An Evolution in Diabetes Mellitu News Widget

⬆️